Beximco Pharma Introduces Affordable Generic for Breakthrough Cystic Fibrosis Treatment
Beximco Pharmaceuticals Ltd., one of Bangladesh’s leading pharmaceutical companies, has announced the global launch of Triko, a highly affordable generic version of Trikafta—the breakthrough triple-combination therapy for cystic fibrosis (CF) developed by Vertex Pharmaceuticals (USA).
Cystic fibrosis is a rare, life-threatening genetic disorder that severely limits life expectancy. Worldwide, around 189,000 people are estimated to live with CF, yet only 60% are diagnosed and fewer than 27% receive treatment due to the exorbitant cost of the original therapy.
Against this backdrop, a group of mothers of children with CF launched a community-led global buyers’ club to help patients access Beximco Pharma’s affordable generic version, unveiled as Triko, during the North American Cystic Fibro...